Year | 2015 | 2017 | 2018 | 2019 | 2020 | P |
---|---|---|---|---|---|---|
No. of available beds (No. of surveyed wards) | 1135 (35) | 1345 (40) | 1359 (44) | 1375 (46) | 1357 (50) | – |
No. of patients admitted | 1018 | 1150 | 1173 | 1214 | 1182 | NA |
No. of patients on antimicrobials | 558 (55%) | 519 (45%) | 592 (50%) | 589 (49%) | 558 (47%) | 0.02 |
No. of patients on antibacterials for systemic use (J01) | 550 (54%) | 504 (44%) | 562 (48%) | 550 (45%) | 501 (42%) | < 0.01 |
Age, median years (range) | 73 (16–99) | 69 (17–100) | 71 (17–100) | 72 (15–99) | 71 (16–101) | – |
Male | 290 (53%) | 281 (54%) | 340 (57%) | 345 (59%) | 330 (59%) | – |
Medical patients | 704 (69%) | 802 (70%) | 849 (72%) | 914 (75%) | 912 (77%) | < 0.01 |
Surgical patients | 278 (27%) | 297 (26%) | 290 (25%) | 273 (22%) | 226 (19%) | < 0.01 |
Intensive care patients | 36 (4%) | 51 (4%) | 34 (3%) | 27 (2%) | 44 (4%) | 0.27 |
No. of antimicrobials | 768 | 755 | 839 | 821 | 780 | – |
Antibacterials for systemic use (J01) | 727 (95%) | 647 (86%) | 692 (82%) | 665 (81%) | 615 (79%) | – |
Antimalarials (P01BA) | 0 | 2 (0.2%) | 0 | 10 (1%) | 4 (0.5%) | – |
Antimycobacterials (J04) | 21 (3%) | 51 (7%) | 50 (6%) | 44 (5%) | 52 (7%) | – |
Antimycotics for systemic use (J02) | 11 (1%) | 19 (3%) | 13 (2%) | 18 (2%) | 20 (3%) | – |
Antivirals for systemic use (J05) | 8 (1%) | 26 (3%) | 80 (10%)* | 70 (9%) | 83 (11%) | – |
Intestinal anti-infectives (A07A) | 1 (< 1%) | 10 (1%) | 4 (< 1%) | 14 (2%) | 6 (< 1%) | – |